COVID-19 and Substance Use Disorders: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine (ISAM) Practice and Policy Interest Group Position Paper

Basic and Clinical Neuroscience

ARTICLE

Farhoudian, Ali¹  Baldacchino, Alexander²  Clark, Nicolas³  Gerra, Gilberto⁴  Ekhtiari, Hamed⁵  Dom, Geert⁶  Mokri, Azarakhsh¹  Sadeghi, Mandana⁷  Nematollahi, Pardis⁸  Demasi, Maryanne³  G. Schütz, Christian⁹  Hashemian, Seyed Mohammadreza^1,10  Tabarsi, Payam^1,11  Galea-singer, Susanna^1,12  Carrà, Giuseppe^1,13  Clausen, Thomas^1,14  Kouimtsidis, Christos^1,15  Tolomeo, Serenella^1,16  Radfar, Seyed Ramin¹  Razaghi, Emran Mohammad¹ 

[1] Department of Psychiatry, Tehran University of Medical Sciences, Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences;Division of Population and Behavioral Sciences, St Andrews University Medical School, University of St Andrews;North Richmond Community Health, Royal Melbourne Hospital;Drug Prevention and Health Branch, Division for Operations, United Nations Office on Drugs and Crime;Laureate Institute for Brain Research;Collaborative Antwerp Psychiatric Research Institute, University of Antwerp;Aftab Mehrvarzi Substance Abuse Treatment Center;Cancer Prevention Research Center, Isfahan University of Medical Sciences;Department of Psychiatry, University of British Columbia;Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences;Clinical Tuberculosis and Epidemiology Research Center, National Research Institute for Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences;Institute for Innovation and Improvement, Centre for Addictions Research, University of Auckland;Department of Medicine and Surgery, Section of Psychiatry, University of Milan Bicocca;Norwegian Centre for Addiction Research (SERAF), University of Oslo;Ministry of Health;Department of Psychology, National University of Singapore (NUS);Integrated Substance Abuse Programs, University of California

关键词: Coronavirus;    Coronavirus Disease 2019 (COVID-19);    Pandemic;    Public health;    Substance use disorder;    Addiction medicine;    Harm reduction;    Policy;    Methadone;    Opioid substitution therapy;   

DOI  :  10.32598/bcn.11.covid19.1

来源: Iran University of Medical Sciences

【 摘 要 】

Coronavirus Disease 2019 (COVID-19) is escalating all over the world and has higher morbidities and mortalities in certain vulnerable populations. People Who Use Drugs (PWUD) are a marginalized and stigmatized group with weaker immunity responses, vulnerability to stress, poor health conditions, high-risk behaviors, and lower access to health care services. These conditions put them at a higher risk of COVID-19 infection and its complications. In this paper, an international group of experts on addiction medicine, infectious diseases, and disaster psychiatry explore the possible raised concerns in this issue and provide recommendations to manage the comorbidity of COVID-19 and Substance Use Disorder (SUD).

【 授权许可】

Unknown